Mr. Zhou Gaobo, the Chief Investment Officer of Simcere Pharmaceutical Group (2096.HK). He is in charge of the company's innovative drug investment and business development, establishment of new investment platforms, as well as the investment strategy planning and practice. Before joining Simcere, Mr. Gaobo Zhou was a Partner at McKinsey & Company and co-leader of the Greater China Healthcare practice. He has fifteen years of experience in management consulting in the healthcare industry. He worked with leading pharmaceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in China Healthcare Reform and innovation, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development. Mr. Gaobo Zhou holds an MBA from Duke University, a Master's Degree in Biochemistry from the University of Maryland and a Bachelor’s Degree in Genetics from Fudan University. |